Quick Answer
Cartesian Therapeutics, Inc. reported Net Income Loss of -$130.30 million for the year ending 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -68.3% in Net Income Loss from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Cartesian Therapeutics, Inc.'s Net Income Loss has declined by 911.7%.
- Historical annual values: Fiscal year 2025: -$130.30 million | Fiscal year 2024: -$77.42 million | Fiscal year 2023: -$219.71 million | Fiscal year 2022: $35.38 million | Fiscal year 2021: -$25.69 million | Fiscal year 2020: -$68.88 million | Fiscal year 2019: -$55.35 million | Fiscal year 2018: -$65.34 million | Fiscal year 2017: -$65.32 million | Fiscal year 2016: -$36.21 million | Fiscal year 2015: -$25.17 million | Fiscal year 2014: -$12.88 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: